Henrik Orum

USPTO Granted Patents = 14 (Patent Applications = 18)

EPO Patents = 2

Average Co-Inventor Count = 4.7

ph-index = 6

Forward Citations = 306(Granted Patents)

Location History:

Varlose, DK (2000 - 2001)
Værløse, DK (2013)
Vaerlose, DK (1998 - 2021)

Company Filing History:

6 out of 46

Roche Innovation Center Copenhagen A/s

Roche Diagnostics Gmbh

Boehringer Mannheim Gmbh

patents

6. 1 out of 2,072

Georgia Tech Research Corporation

patents

7. 1 out of 832,680

Other

patents

where one patent can have more than one assignee

Years Active: 1998-2021

Loading Chart...

14 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 11155816 - Oligonucleotide conjugates (2021-10-26),

2. 10077443 - Oligonucleotide conjugates (2018-09-18),

3. 9738894 - Short interfering RNA (siRNA) analogues (2017-08-22),

4. 9566293 - Oral delivery of therapeutically effective LNA oligonucleotides (2017-02-14),

5. 9364495 - Oral delivery of therapeutically effective LNA oligonucleotides (2016-06-14),

6. 9297010 - Short interfering RNA (siRNA) analogues (2016-03-29),

7. 8580756 - Short oligomer antagonist compounds for the modulation of target mRNA (2013-11-12),

8. 7622453 - Oligomeric compounds for the modulation of Bcl-2 (2009-11-24),

9. 7105318 - Specific and sensitive nucleic acid detection method (2006-09-12),

10. 6346378 - Nucleic acid analogs with a chelating functionality (2002-02-12),

11. 6225052 - Method for determining a nucleic acid (2001-05-01),

12. 6117973 - PNA monomers with electron donor or acceptor (2000-09-12),

13. 5861250 - Protecting nucleic acids and methods of analysis (1999-01-19),

14. 5843663 - Methods of capturing nucleic acid analogs and nucleic acids on a solid (1998-12-01),

Title: The Innovative Contributions of Henrik Orum

Introduction

Henrik Orum is a prominent inventor based in Vaerlose, Denmark. He has made significant contributions to the field of oligonucleotide therapeutics, holding a total of 14 patents. His work focuses on enhancing the properties of oligonucleotides, which are crucial for therapeutic applications.

Latest Patents

Among his latest patents, Henrik Orum has developed innovative oligonucleotide conjugates. These inventions relate to the use of a cleavable phosphodiester region that is covalently attached to a conjugate, targeting group, or blocking group. This approach aims to improve the therapeutic index of oligonucleotides, thereby enhancing their effectiveness in medical treatments.

Career Highlights

Throughout his career, Henrik Orum has worked with notable companies such as Roche Innovation Center Copenhagen A/S and Santaris Pharma A/S. His experience in these organizations has allowed him to contribute to groundbreaking research and development in the field of biotechnology.

Collaborations

Henrik has collaborated with esteemed colleagues, including Henrik Frydenlund Hansen and Troels Koch. These partnerships have fostered a collaborative environment that promotes innovation and the advancement of therapeutic solutions.

Conclusion

Henrik Orum's contributions to oligonucleotide therapeutics exemplify the impact of innovative thinking in the medical field. His patents and collaborations continue to influence the development of effective therapeutic strategies.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

18 patents pending:

Please report any incorrect information to support@idiyas.com

2 patents (EPO):

Please report any incorrect information to support@idiyas.com

Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.